Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ManKind Presents Positive Original Analyses of Afrezza\u00ae Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Large molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mankind Pharma Launches Drug to Treat Black Fungus","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mankind Pharma Gets CDSCO Panel Nod for Phase I Trial of Anti-Diabetic Drug, MKP10241","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Preclinical"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mankind Pharma Launches Justoza to Treat Diabetes, Heart Failure & CKD","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mankind Pharma to Launch Cheapest Covid Antiviral Drug Molnupiravir at Rs 35 Per Capsule by Next Week : Report","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mankind Pharma to Acquire Combihale and Daffy Brands From Dr Reddy's Laboratories","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Panacea Biotec Limited","pharmaFlowCategory":"D","amount":"$251.1 million","upfrontCash":"Undisclosed","newsHeadline":"Panacea Biotec Sells Domestic Formulation Assets To Mankind Pharma for Rs 1,908 Crore","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Actimed Therapeutics","pharmaFlowCategory":"D","amount":"$12.1 million","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Successfully Closes Second Tranche Of \u00a310m Seed Financing To Progress Pipeline For Treatment Of Cancer Cachexia And Other Muscle Wasting Disorders","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Actimed Therapeutics","pharmaFlowCategory":"D","amount":"$6.3 million","upfrontCash":"Undisclosed","newsHeadline":"Actimed Therapeutics Closes Over-Subscribed Series A Financing Round of \u00a35 Million to Advance Clinical Development of Lead Programme for Cancer Cachexia","therapeuticArea":"Nutrition and Weight Loss","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Nutrition and Weight Loss","graph2":"Phase II"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mankind Pharma Enters Exclusive Pact to Distribute Astrazeneca's Anti-Asthma Drug Symbicort in India","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Mankind Pharma

    Menu

    Mankind Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    SERVICES

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Mankind Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mankind Pharma Enters Exclusive Pact to Distribute Astrazeneca's Anti-Asthma Drug Symbicort in India

              Details:

              Under the agreement, Mankind Pharma will distribute AstraZeneca's anti-asthma inhaled corticosteroid drug Symbicort, (budesonide/formoterol) approved to treat asthma and COPD, in India.

              Lead Product(s): Budesonide,Formoterol Fumarate

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Symbicort

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: AstraZeneca

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 13, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mankind Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Closes Over-Subscribed Series A Financing Round of £5 Million to Advance Clinical Development of Lead Programme for Cancer Cachexia

              Details:

              The investment will support the development of the Actimed pipeline, including ACM-001.1 (S-pindolol benzoate), with preparations under way for a Phase 2b/3 programme targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorectal cancer.

              Lead Product(s): S-pindolol Benzoate

              Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-001.1

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Actimed Therapeutics

              Deal Size: $6.3 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing June 26, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mankind Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Actimed Therapeutics Successfully Closes Second Tranche Of £10m Seed Financing To Progress Pipeline For Treatment Of Cancer Cachexia And Other Muscle Wasting Disorders

              Details:

              ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.

              Lead Product(s): Pindolol

              Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-001.1

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Actimed Therapeutics

              Deal Size: $12.1 million Upfront Cash: Undisclosed

              Deal Type: Financing January 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mankind Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mankind Pharma to Acquire Combihale and Daffy Brands From Dr Reddy's Laboratories

              Details:

              The acquisition of “Combihale” is expected to strengthen Mankind’s presence in the inhalation respiratory market segment. Daffy is a soap-free moisturising bar for infant babies.

              Lead Product(s): Formoterol Fumarate,Fluticasone Propionate

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Combihale

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Dr. Reddy\'s Laboratories

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition February 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mankind Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Panacea Biotec Sells Domestic Formulation Assets To Mankind Pharma for Rs 1,908 Crore

              Details:

              The top selling brands are Pangraf (tacrolimus), Alphadol (alfacalcidol), Cilamin (penicillamine) & Livoluk Fibre (lactulose in combination with ispaghula) were ranked number 1, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were among the top 5.

              Lead Product(s): Tacrolimus

              Therapeutic Area: Dermatology Product Name: Pangraf

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Panacea Biotec Limited

              Deal Size: $251.1 million Upfront Cash: Undisclosed

              Deal Type: Agreement February 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mankind Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mankind Pharma to Launch Cheapest Covid Antiviral Drug Molnupiravir at Rs 35 Per Capsule by Next Week : Report

              Details:

              Mankind pharma launched Molulife (Molnupiravir) developed by MSD and Ridgeback Biotherapeutics by next week, It is also expected that Cipla, Sun pharma, and DRL will also release Molnupiravir in the coming weeks for the treatment of patients with severe COVID19.

              Lead Product(s): Molnupiravir

              Therapeutic Area: Infections and Infectious Diseases Product Name: Molulife

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mankind Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mankind Pharma Launches Justoza to Treat Diabetes, Heart Failure & CKD

              Details:

              Mankind Pharma has launched Justoza, a Dapagliflozin brand marketed by Mankind to treat diabetes, heart failure and chronic kidney disease. Launching API DMF grade dapagliflozin is an innovative futuristic approach to provide the best in class quality to the patients.

              Lead Product(s): Dapagliflozin

              Therapeutic Area: Endocrinology Product Name: Justoza

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mankind Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mankind Pharma Gets CDSCO Panel Nod for Phase I Trial of Anti-Diabetic Drug, MKP10241

              Details:

              MKP10241, a new class of anti-diabetic molecules, is designed and developed at the Mankind Research Centre. It is a potent and orally administered small molecule, GPR119 agonist. GPR 119 is highly expressed in pancreatic beta cells and intestinal enteroendocrine cells.

              Lead Product(s): MKP10241

              Therapeutic Area: Endocrinology Product Name: MKP10241

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mankind Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Mankind Pharma Launches Drug to Treat Black Fungus

              Details:

              Posaconazole has been found to be a safer and effective drug of choice for the management of the disease. The drug has received approval from the Drug Controller General of India (DCGI).

              Lead Product(s): Posaconazole

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mankind Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ManKind Presents Positive Original Analyses of Afrezza® Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions

              Details:

              Company announced that new data from clinical studies of Afrezza® demostrating safe and effective dosing, its association with weight loss in patients with type 2 diabetes, and an evaluation of a comprehensive two year safety study showing that significant changes in FEV1.

              Lead Product(s): Insulin

              Therapeutic Area: Endocrinology Product Name: Afrezza

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY